Rakesh Verma is a Drug development & Clinical Translational Leader with more than 15 years of experience in immuno-oncology, hematology, and oncology. Rakesh most recently led ARMO Biosciences as Site-Head and drove the successful M&A of ARMO ($1.6 Bn) with Eli Lilly. Rakesh has led IND development of Cytokine-based drug development at Eli Lilly as their VP level executive for early phase development. He is a highly adaptable scientific leader with a proven record of dealing with rapid growth and development. He works effectively with the scientific and executive teams using data and problem-solving techniques to support the strategic vision of the organization.
